Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line Treatment of Helicobacter pylori with Lactobacillus casei rhamnosus LCR35 Alone or with Levofloxacin-based Sequential Therapy
2017-005111-14Phase 3Terminated
- Sponsor
- Kepler Universitätsklinikum
- Start
- Apr 2019
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Helicobacter pylori infection comparing Levofloxacin-based sequential therapy + LCR35 with Levofloxacin-based sequential therapy + placebo (2 arms). Started Apr 2019; status: terminated.
02
Drugs
lactobacillus rhamnosus Lcr35
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on 2017-005111-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005111-14.